ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladde...
ImmunityBio, Inc. (IBRX)
Company Research
Source: Business Wire
Results from the QUILT-3.032 study of 80 subjects, published in The Journal of Urology, showed 96% disease-specific survival and 83% progression-free survival at 36 months, demonstrating the long-term duration of effect of ANKTIVA® in patients with high-grade papillary NMIBC without CIS1High cystectomy avoidance rates of 92% and 82% were seen at 12 months and 36 months1, validating the durable response and bladder sparing effect of ANKTIVA plus BCG in this indicationANKTIVA plus BCG demonstrated a tolerable safety profile consistent with BCG alone, with 3% of grade 3 and no grade 4 or 5 treatment-related adverse events1There are currently no approved therapies for BCG-unresponsive papillary-only NMIBC, leaving patients with total radical cystectomy as the alternative despite its high mortality and morbidity CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pm
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio (NASDAQ:IBRX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Should EMA's Conditional Nod for ANKTIVA in High-Risk Bladder Cancer Require Action From ImmunityBio (IBRX) Investors? [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
- ImmunityBio, Novo, Moderna among winners of EU drug recommendations this week [Seeking Alpha]Seeking Alpha
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 3
- 12/15/25 - Form 8-K
- IBRX's page on the SEC website